Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

151
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
151
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

893
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
893
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.9K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

139
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
139

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biocompatible and long-acting polyphosphate inhibitors for the diagnosis and treatment of thrombosis and thromboembolism.

Biomaterials advances·2026
Same author

Synergistic Thrombolysis-Antiplatelet Therapy of Engineered tPA Variant citPA5 and Tirofiban in a Mouse Stroke Model.

Thrombosis and haemostasis·2026
Same author

Corrigendum "Anticancer effects of salidroside on ovarian cancer carcinogenesis and molecular mechanism in mice" [Biomed. Pharmacother. 198 (2026) 119250].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Internal insertion in albumin improves fusion-protein integrity while maintaining bioactivity and FcRn interaction.

International journal of biological macromolecules·2026
Same author

Kisspeptin-10 Promotes Hormone Secretion, Ovarian Follicles Development and Fecundity via PI3K/AKT/ERK Signal Pathway in Mice.

Molecular reproduction and development·2026
Same author

Anticancer effects of salidroside on ovarian cancer carcinogenesis and molecular mechanism in mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Related Experiment Video

Updated: Dec 1, 2025

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.2K

[Recent progress in developing of thrombolytic agents for ischemic stroke].

Yanyan Xu1, Shanli Chen2, Dan Chen2

  • 1College of Biological Science and Engineering, Fuzhou University, Fuzhou 350116, Fujian, China.

Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology
|November 10, 2020
PubMed
Summary

Ischemic stroke treatment faces challenges with current clot-dissolving drugs like tissue plasminogen activator (tPA). Recent advancements focus on developing improved thrombolytic therapies to overcome limitations and enhance patient outcomes.

Keywords:
ischemic strokethrombolysistissue plasminogen activator

More Related Videos

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.3K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K

Related Experiment Videos

Last Updated: Dec 1, 2025

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.2K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.3K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.2K

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Ischemic stroke is a leading cause of death and disability worldwide.
  • Current treatments, primarily tissue plasminogen activator (tPA), have limitations including a narrow therapeutic window and bleeding risks.
  • Effective thrombolysis is crucial for restoring blood flow and minimizing brain damage.

Purpose of the Study:

  • To review recent advancements in thrombolytic drugs and treatment strategies for ischemic stroke.
  • To highlight progress in overcoming the limitations of existing therapies.
  • To provide insights for the development of novel thrombolytic agents.

Main Methods:

  • Comprehensive literature review of recent research on thrombolytic therapies.
  • Analysis of studies focusing on tissue plasminogen activator (tPA) and alternative approaches.
  • Synthesis of findings from both published data and the authors' own contributions.

Main Results:

  • Significant progress has been made in developing new thrombolytic drugs and strategies.
  • Research is actively addressing the limitations associated with tPA, such as bleeding complications.
  • Novel approaches aim to improve clot dissolution efficiency and safety profiles.

Conclusions:

  • The field of thrombolytic therapy for ischemic stroke is rapidly evolving.
  • Continued research and development are essential for creating more effective and safer treatments.
  • Future innovations hold promise for improving outcomes for stroke patients.